Mark R. Storey, MD
Dr. Mark Storey was born in Hot Springs, Arkansas and graduated from Vanderbilt University with honors with a BE in Biomedical Engineering. He returned to Arkansas for medical school and then performed his residency training in Radiation Oncology at MD Anderson Cancer Center in Houston from 1997-2001. After completing his oncology training he returned to his home state and practiced in North Little Rock for nearly 18 years.
During that period, he served as President of the Radiation Oncology Associates PA for over 10 years which is a 7-8 member physician team covering 5 facilities across the state of Arkansas. His North Little Rock clinic consistently performed in the top 1% to 3% nationally for patient satisfaction based on third party Press Ganey survey data during his 18 year leadership. He developed and started the IMRT program for his collection of practices in 2001. He initiated forward planning for breast cases in North Little Rock in 2003. Under his leadership, the North Little Rock center was the first radiation oncology center in the region to move to a fully electronic medical chart in 2009. The center began the hypofractionated breast treatments (~3 weeks versus ~6 weeks) in 2009 to reduce patient time and expense. Time and again, he has pushed for world class, current, highest quality care.
In late 2016, he began to re-visit the area of Proton Therapy. His long-term interest in Proton Therapy dates back to 2000 and 2001 when MD Anderson Cancer Center was preparing to build their facility which opened subsequently in 2006 (these are big projects). Over the course of 2017 and 2018, he became convinced that the technology had progressed and that Proton Therapy had the opportunity to become the best available treatment for many cancer patients. He has worked diligently to bring Proton Therapy to Arkansas and one is currently under construction at the University of Arkansas for Medical Sciences, at least in part due to his work and effort. That said, in 2019 there was no center in the state of Arkansas. So he and his family have moved to Oklahoma City, OK and are starting a new phase of life to help move the Standard of Care forward for the Oklahoma City community and region with the longer term goals to become involved Nationally to promote education and awareness regarding the benefits of Proton Therapy.
In 2019 with the move to Oklahoma City, Proton Radiation Oncology, PLLC was founded by Dr. Mark Storey with the goal of expanding and improving patient access to Proton Therapy. The goal for Proton Radiation Oncology, PLLC is simple - increase access and awareness to proton therapy while providing high level standard of care radiation. To reach that goal, we’ve partnered with the Oklahoma Proton Center. We believe the Oklahoma Proton Center serves as a great fit with our goals to increase access to proton therapy for cancer patients. The center is a nearly 60,000 square foot facility with 4 proton treatment rooms, making it one of the largest facilities in the US dedicated to Proton Therapy for cancer treatment. It was the 6th facility in the nation and treated nearly 3000 patients over that 10 year period. The center has one of the most experienced staffs in the nation using Proton Therapy to treat complex cancer cases.
The aim is simple: treat and care for patients as if they are family. Do everything we can to kill the cancer and minimize the damage of radiation by utilizing unsurpassed equipment, state of the art software. And then, importantly, pair that technical excellence with a caring attentive clinically focused staff. We believe we can build that radiation oncology practice through our partnership at the center in Oklahoma City.
Find out more:
We understand that finding the right physician and facility to have your cancer treated is a choice not to be taken lightly. We believe understanding all available treatment options for your cancer is a critical step and we are happy to meet with you to review your case. It isn’t a fit for all patients, but for some it can dramatically improve your treatment. If it doesn’t benefit your case, we’ll work with you to help navigate your diagnosis.
Mark Storey MD
President Proton Radiation Oncology, PLLC
Radiation Facility Information:
405.454.7978
Oklahoma Proton Center
5901 West Memorial Road
Oklahoma City, OK 73142
www.okcproton.com
ACCREDITATIONS:
American Board of Radiology, Radiation Oncology DABR
ACTIVE LICENSES:
Oklahoma, Arkansas, Tennessee
EDUCATION:
MD ANDERSON CANCER CENTER
Residency in Radiation Oncology, 2001
UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES
Medical Doctorate, 1996
VANDERBILT UNIVERSITY
B.E., Biomedical Engineering, 1992
PEER REVIEWED PUBLICATIONS:
Rana S, Eckert C, Singh H, Zheng Y, Chacko M, Storey M, Chang J. Determination of machine-specific tolerances using statistical process control analysis of long-term uniform scanning proton machine QA results. Radiation Oncology Physics. Sept 2020: 9; 163-170. DOI: 10.1002/acm2.12990
Rana S, Storey M, Padannayil N, et al. Investigating the utilization of beam-specific apertures for the intensity-modulated proton therapy (IMPT) head and neck cancer plans. Medical Dosimetry, 2020, 10.006.
Grewal H, Chacko M, Rana S,Jin H, Storey M and Chang J. Single institution’s experience with clinical implementation of uniform scanning proton beams for ocular melanoma treatment. AAPM 2020 Conference Poster Presentation
Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):635-42.
Storey MR, Munden R, Strom EA, McNeese MD, Buchholz TA. Coronary artery dosimetry in intact left breast irradiation.,Cancer J. 2001 Nov-Dec;7(6):492-7.
Storey MR, Garden AS, Morrison WH, Eicher SA, Schechter NR, Ang KK. Postoperative radiotherapy for malignant tumors of the submandibular gland. Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):952-8.
Storey MR, Landgren RC, Cottone JL, Stallings JW, Logan CW, Fraiser LP, Ross CS, Kock RJ, Berkley LW, Hauer-Jensen Transperineal 125iodine implantation for treatment of clinically localized prostate cancer M. Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):565-7.